Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ACP Immunotherapy Workshop /
Combination immunotherapies and multi-modal treatment

13th Oct 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.10.17
Views: 1659

Dr Paul Nathan - Mount Vernon Hospital, Northwood, UK

Dr Nathan speaks with ecancer at the ACP immunotherapy workshop about combined immunotherapies and the potential pitfalls of added modalities.

He outlines successes of combined ipilimumab and nivolumab in treating melanoma and kidney cancer, and how toxicities can be managed, noting that patients with more significant adverse reactions simultaneously experience better curative response too.

Dr Nathan highlights the flaws in relying in early data for response and toxicity, and the rights of patients in communication of treatment suitability and availability.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation